Comprehensive analysis of ITI Pharma and Healthcare Fund (IDCW) (42389) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
ITI Asset Management Ltd
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Weak Returns
High Risk
High Expenses
Equity Focused
Established Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Market exposure level
Outperformance vs benchmark
Historical performance consistency
Recent performance momentum
Fund manager experience
Risk-adjusted returns
Assets under management
Fund management costs
This fund has underperformed its benchmark by 1.75% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 10.93% |
| Divis Laboratories Ltd | Pharmaceuticals | 8.68% |
| Max Healthcare Institute Ltd | Healthcare | 6.12% |
| Apollo Hospitals Enterprise Ltd | Healthcare | 5.66% |
| Cohance Lifesciences Ltd | Pharmaceuticals | 4.66% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals | 4.58% |
| Aurobindo Pharma Ltd | Pharmaceuticals | 3.66% |
| Fortis Healthcare Ltd | Healthcare | 3.51% |
| Lupin Ltd | Pharmaceuticals | 3.46% |
| Aster DM Healthcare Ltd | Healthcare | 3.19% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 6M | 1Y | 3Y |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1540.61 | 20.90% | -2.29% | 13.00% |
| Aditya Birla SL MNC Fund - (G) | ₹1383.22 | 20.48% | -2.95% | 12.20% |
| Nippon India Banking&Financial Services-Dir(G) | ₹662.94 | 13.57% | 4.61% | 17.80% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹662.94 | 13.57% | 4.61% | 17.80% |
| Nippon India Banking&Financial Services (G) | ₹606.00 | 13.09% | 3.74% | 16.83% |
| Nippon India Banking&Financial Services (Bonus) | ₹606.00 | 13.09% | 3.74% | 16.83% |
| Nippon India Pharma Fund - Direct (G) | ₹574.98 | 13.30% | 0.45% | 24.37% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹574.98 | 13.30% | 0.45% | 24.37% |
| Franklin India Technology Fund - Direct (G) | ₹565.29 | 7.85% | -5.66% | 23.50% |
| ICICI Pru FMCG Fund - Direct (G) | ₹542.41 | 13.18% | -7.36% | 10.35% |
A seasoned investment professional with over 4 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.